AI Article Synopsis
- The COVID-19 pandemic continues until enough herd immunity is achieved through natural infections or vaccinations.
- Researchers designed two vaccine candidates focused on the immunodominant sites of the SARS-CoV-2 spike protein: one targeting just the Receptor Binding Domain (RBD) and another targeting all major sites.
- The study showed that the vaccine targeting all sites (S-ID) was more effective, leading to better antibody responses and reduced symptoms in vaccinated hamsters compared to the RBD-specific vaccine.
Article Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118541 | PMC |
| http://dx.doi.org/10.1080/22221751.2021.1921621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!